Skip Navigation


Nucleic Acids Research Advance Access originally published online on December 26, 2007
Nucleic Acids Research 2008 36(4):1209-1219; doi:10.1093/nar/gkm1131
This Article
Right arrow Abstract Freely available
Right arrow Print PDF (4366K) Freely available
Right arrow Screen PDF (421K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
36/4/1209    most recent
gkm1131v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Yu, M.
Right arrow Articles by Yang, X. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, M.
Right arrow Articles by Yang, X. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2008, Vol. 36, No. 4 1209-1219
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Molecular Biology

Proteomic screen defines the hepatocyte nuclear factor 1{alpha}-binding partners and identifies HMGB1 as a new cofactor of HNF1{alpha}

Miao Yu1,2,3, Jian Wang1,2,3, Wei Li1,2,3, Yan Zhi Yuan1,2,3, Chang Yan Li1,3, Xiao Hong Qian1,2,3, Wang Xiang Xu1,3, Yi Qun Zhan1,3 and Xiao Ming Yang1,2,3,*

1Beijing Institute of Radiation Medicine, Beijing, 100850, 2Beijing Proteomics Research Center, Beijing, 102206 and 3State Key Laboratory of Proteomics, Beijing, 100850, P. R. China

*To whom correspondence should be addressed. Tel: +86 10 66931424; Fax: +86 10 68212874; Email: xmyang2{at}nic.bmi.ac.cn or xiaomingyang{at}sina.com

Received September 11, 2007. Revised November 28, 2007. Accepted December 5, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 SUPPLEMENTARY DATA
 REFERENCES
 
Hepatocyte nuclear factor (HNF)-1{alpha} is one of the liver-enriched transcription factors involved in many tissue-specific expressions of hepatic genes. The molecular mechanisms for determining HNF1{alpha}-mediated transactivation have not been explained fully. To identify unknown proteins that interact with HNF1{alpha}, we developed a co-IP-MS strategy to search HNF1{alpha} interactions, and high mobility group protein-B1 (HMGB1), a chromosomal protein, was identified as a novel HNF1{alpha}-interacting protein. In vitro glutathione S-transferase pull-down and in vivo co-immunoprecipitation studies confirmed an interaction between HMGB1 and HNF1{alpha}. The protein–protein interaction was mediated through the HMG box domains of HMGB1 and the homeodomain of HNF1{alpha}. Furthermore, electrophoretic mobility shift assay and chromatin-immunoprecipitation assay demonstrated that HMGB1 was recruited to endogenous HNF1{alpha}-responsive promoters and enhanced HNF1{alpha} binding to its cognate DNA sequences. Moreover, luciferase reporter analyses showed that HMGB1 potentiated the transcriptional activities of HNF1{alpha} in cultured cells, and downregulation of HMGB1 by RNA interference specifically affected the HNF1{alpha}-dependent gene expression in HepG2 cell. Taken together, these findings raise the intriguing possibility that HMGB1 is a new cofactor of HNF1{alpha} and participates in HNF1{alpha}-mediated transcription regulation through protein–protein interaction.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 SUPPLEMENTARY DATA
 REFERENCES
 
The transcriptional factor hepatocyte nuclear factor (HNF)-1{alpha} is an atypical homeodomain-containing protein identified by binding to similar regulatory cis-elements present in special genes (1–3). Binding sites for HNF1{alpha} have been shown in the promoters or enhancers of genes that express almost exclusively in liver, such as albumin (ALB), {alpha}-fetoprotein (AFP), {alpha}-fibrinogen (FGA), {alpha}1-antitrypsin (A1AT), transthyretin (TTR) and aldolase B (ALDOB) (3–6). HNF1{alpha} can also modulate transcription indirectly through transcription factor networks, including the HNF1{alpha}-mediated negative regulation of genes activated by HNF4{alpha}, which means that HNF1{alpha} plays a central role in the fine tuning of hepatocyte-specific gene expression via its indirect negative autoregulatory mechanism (7). HNF1{alpha} expression was first regarded as a hepatocyte-specific transcriptional regulator; later its expression was also found in kidney, intestine and endocrine pancreas (1,2). Further studies revealed that HNF1{alpha} played an important role in the transcriptional activation of genes critical for their functions of these tissues (8–11). Mutations in HNF1{alpha} gene have been identified in patients with Maturity Onset Diabetes of the Young (MODY3) (12). Moreover, it has been reported that expression of an HNF1{alpha}-dominant negative mutant linked to MODY3 led to an impaired function of pancreatic β-cells (13,14). The loss of HNF1{alpha} has been shown during renal carcinogenesis, which is usually accompanied by dedifferentiation processes, including the loss of tissue-specific gene expression (15).

HNF1{alpha} uses a POU-homeodomain sequence and a myosin-like dimerization domain located at the amino terminus of the protein to bind its DNA recognition sequence as a dimmer (3,16). Two characteristics of HNF1{alpha}, which is special among the homeodomain-containing proteins, distinguish it from other homeodomain transcription factors. First, its DNA-binding domain contains a 21-amino acid insertion between the highly conserved {alpha} helices 2 and 3, which is not found in any other homeodomains. Second, HNF1{alpha} binds to its target genes as a dimmer and it dimerizes in absence of its DNA recognition sequence (2). The C-terminal part of HNF1{alpha} contains three regions that are necessary for transcriptional activation (2). The ability of various HNF1{alpha} domains to interact with multiple coactivators allows the formation of a platform for recruitment of a transcriptional complex, leading to a strong enhancement of transcription. PCBD1 (its another name is DcoH) is a dimerization cofactor of HNF1{alpha}, which selectively stabilizes HNF1{alpha} homodimers and enhances HNF1{alpha}-mediated transcriptional activity through making of a tetrameric complex (17). HNF1{alpha} also can physically interact with histone acetyltransferases (HATs), CREB-binding protein (CBP), p300/CBP-associated factor (P/CAF), SRC-1 and RAC3 (18). CBP/p300 interacts with both the DNA-binding domain and the activation domain of HNF1{alpha} while P/CAF, SRC-1 and RAC3 interacts with the HNF1{alpha} activation domain (19). These results support a model that involves the combined action of multiple coactivators recruited by HNF1{alpha}, which activate transcription by coupling nucleosome modification and recruitment of the general transcription machinery. HNF1{alpha} also interacts with GATA5, Neurog3 and Cdx2, and the interactions lead to a cooperative enhancement of HNF1{alpha}-mediated activation of transcription (20–22). A synergy between HNF4{alpha} and HNF1{alpha} has been reported too (23). However, the molecular mechanisms for determining HNF1{alpha}-mediated transactivation have not been explained fully.

In this work, we identified the HNF1{alpha}-binding partners by co-IP combined with mass spectrometry strategy and found that HMGB1 functioned as a potential coactivator of HNF1{alpha} through direct interaction between the HMG box domain of HMGB1 and homeodomain of HNF1{alpha}.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 SUPPLEMENTARY DATA
 REFERENCES
 
Plasmid constructions
The human full-length HNF1{alpha}, HMGB1 and HMGA2 were amplified by polymerase chain reaction (PCR) from the human liver cDNA and cloned into the pcDNA3.1/Myc-HisB vector (Invitrogen, Carlsbad, CA, USA). The HNF1{alpha} deletion constructs were generated through ligation of PCR products amplified from the pcDNA3.1-HNF1{alpha}. The various HNF1{alpha} constructs were cloned into the pGEX4T2 vector (Amersham Pharmacia, Piscataway, NJ) using indicated sites (Supplementary Data 1). The HMGB1 deletion constructs were generated by PCR cloning and inserted into pcDNA3.1/Myc-HisB. For subcellular localization assays, HMGB1 cDNA was cloned into pEGFP-N1 (Clontech, Palo Alto, CA). The sequences of primers used in plasmid constructions are shown in Supplementary Data 1.

The Renilla luciferase expression vector (pRL-TK) was purchased from Promega (Madison, WI) and luciferase reporter plasmid pGL3-AFP was kindly provided by Dr Huang Ailong (Chongqing University of Medical Sciences, China).

Co-immunoprecipitation
HepG2 cells were cultured in Dulbecco's modified Eagle's medium (Gibco/BRL, Rockville, MD) supplemented with 10% fetal bovine serum. After centrifugation and washing with phosphate-buffered saline (PBS), the cell pellets were resuspended and lyzed using Mammalian Protein Extraction Reagent (Pierce, Rockford, IL) according to the protocol.

Three milligrams proteins in 1 ml of lysates were mixed with 2 µg of goat polyclonal antibodies against HNF1{alpha} (C-19, Santa Cruz Biotechnology, Santa Cruz, CA) or goat IgG (sc-2028, Santa Cruz Biotechnology) and incubated 90 min at 4°C with gentle shaking, followed by adsorption to protein G plus-agarose beads (sc-2002, Santa Cruz Biotechnology). After four times of extensive washing to remove nonspecific binding with NETN buffer [20 mmol/l Tris–HCl at pH 8.0, 1 mmol/l EDTA, 0.5% NP-40 and 150 mmol/l NaCl supplemented with protease inhibitor mixture (Roche Diagnostics, Rotkreuz, Switzerland)], the complex was resuspended in SDS sample buffer, separated by 10% SDS–polyacrylamide gel electrophoresis (PAGE). For MS analysis, separated protein bands in the SDS–PAGE gel were visualized by Coomassie brilliant blue staining.

MS analyses
Proteins eluted with 5% acetic acid were denatured, reduced and subjected to tryptic digestion. Resulting peptides were analyzed by microcapillary reverse-phase chromatography electrospray (ESI) MS using an LCQ mass spectrometer (ThermoFinnigan, San Jose, CA) equipped with a combination C18 trap ESI-emitter-microcapillary liquid chromatography column design. Mass spectra were acquired via data-dependent ion selection, which was achieved through automatic switching between single MS and MS/MS modes. Proteins were identified from MS/MS spectra using a database search engine called COMET to search against the latest versions of National Cancer Institute human protein databases. The resulting proteins were analyzed using Peptide Prophet and Interact Programs and validated manually.

Reciprocal immunoprecipitation and western blotting analysis
HepG2 cells were transfected with pcDNA3.1-HMGB1 or the vector alone using VigoFect transfection reagent (Vigorous Biotechnology, China). After 48 h of transfection, cell extracts were immunoprecipitated with anti-Myc antibodies (sc-40, Santa Cruz Biotechnology) at 4°C for 2 h, followed by adsorption to protein A/G plus-agarose beads (sc-2003, Santa Cruz Biotechnology) at 4°C overnight. Bound materials were washed thoroughly four times and eluted with NETN buffer. Following SDS–PAGE, immunoprecipitated proteins were transferred onto polyvinylidene difluoride membranes (Amersham life science, Buckinghamshire, England) and probed with various antibodies. The enhanced chemiluminescence (ECL) system (Santa Cruz Biotechnology) was used for detection.

Subcellular localization assays
For HMGB1 and HNF1{alpha} location, immunofluorescence was performed. HepG2 cells were seeded in 6-well plates, cultured in DMEM supplemented with 10% fetal bovine serum and transfected with GFP-HMGB1 and Myc-HNF1{alpha}. 24 h later, the cells were fixed for 30 min at room temperature with 4% paraformaldehyde in PBS, perforated with 1% Triton X-100 in PBS for 15 min, blocked with 3% BSA in PBS for 2 h, incubated with primary antibody overnight at 4°C and probed with secondary antibody. Primary mouse monoclonal antibodies were used with anti-Myc antibody at 1:50. Secondary antibodies were used with TRITC-labeled anti-mouse antibody at 1:50.

Confocal imaging was performed using Zeiss 510 META system. The green fluorescence was excited at 488 nm with 505–530 nm barrier filter and red fluorescence was simultaneously excited at 543 nm with 560 nm barrier filter.

Generation of recombinant proteins and GST pull-down assays
HNF1{alpha}{Delta}1-189, HNF1{alpha}{Delta}190-319 and HNF1{alpha}{Delta}320-631 fragments were cloned in frame with the glutathione S-transferase (GST) gene of pGEX4T2, respectively. The resulting GST fusion proteins were expressed in Escherichia coli BL21, induced by 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and solubilized from bacteria in lysis buffer (1% Triton X-100 in PBS) by sonication. After centrifugation at 12 000 r.p.m. for 15 min at 4°C, the supernatant was added to the glutathione-Sepharose 4B beads (Amersham Biosciences, Uppsala, Sweden) and mixed gently at 4°C overnight. After binding, the beads were washed four times in cold PBS to remove nonspecific binding. GST, GST-HNF1{alpha}{Delta}1-189, GST-HNF1{alpha}{Delta}190-319 and GST-HNF1{alpha}{Delta}320-631 fusion proteins, as judged by Coomassie bright blue staining, were bound to glutathione-Sepharose beads.

Myc-HMGB1FL protein, Myc-HMGB1{Delta}8-161 protein, Myc-HMGB1{Delta}8-77 protein, Myc-HMGB1{Delta}92-161 protein and Myc-HMGA2 protein were got from the whole-cell lysis of HepG2 cells which were transfected with indicated plasmids as shown in Figure 2C and D. The cell lysis were treated with DNase I (TaKaRa Japan) for 30 min at 37°C to remove the genomic DNA contamination before mixed with GST fusion protein which adsorbed to Sepharose beads. The binding reaction was carried out overnight at 4°C in 1 ml binding buffer (20 mmol/l Tris–HCl at pH 8.0, 150 mmol/l NaCl, 1 mmol/l EDTA, 10% glycerol and 0.1% NP-40). After thoroughly washing, specifically bound proteins were subjected to 15% SDS–PAGE followed by western blotting analysis.

siRNA transfection
The selected target sequence of HMGB1 was 5'-AGACCTGAGAATGTATCCCCAAA-3' on the 3' noncoding region according to the previous description (24). HMGB1 siRNA were as follows: 5'-AGACCUGAGAAUGUAUCCCCAAADdTdT-3' (sense strand), 5'-UUUGGGGAUACAUUCUCAGGUCUdTdT-3' (antisense strand). HepG2 cells were grown in 6-well plates to 50% confluence and HMGB1 siRNA were transfected into HepG2 cells at 100 pmol/well with Vigofect reagent according to the manufacturer's protocol. The nonspecific RNA duplexes were used in control experiments. Cells were harvested after incubation for 48–72 h, and then real-time PCR and western blotting were performed to detect silence effect.

Reverse transcription and real-time PCR
Total RNA isolation and reverse-transcription were applied according to the manufacturer's protocol. The cDNA was analyzed using real-time PCR according to the instruction from the kit. In brief, real-time PCR was done using Bio-Rad IQTM5 Multicolor Real-time PCR Detection System (Bio-Rad Laboratories, Hercules, CA) and SYBR Premix Ex Taq TM (2x) kit (TaKaRa, Japan). The cycling conditions were as follows: 95°C for 1 min, 40 cycles of 10 s at 95°C, 30 s at 55°C and 30 s at 72°C. SYBR Green fluorescence was measured after each elongation step. Specific primers for each gene were listed in Supplementary Data 1. At the end of PCR, a melting curve analysis was performed by gradually increasing the temperature from 55°C to 95°C to determine purity. PCR was set up in triplicates and threshold cycle (Ct) values of the target genes were normalized to the endogenous control. Differential expression was calculated according to the 2–{Delta}{Delta}CT method.

Transfection and luciferase assays
HepG2 cells were transfected with different plasmids as indicate. In each case, vector DNA was added as necessary to achieve a constant amount of transfected DNA (1.25 µg). Cells were collected 36 h later after transfection and lyzed in 100 µl 1x passive lysis buffer (Promega). Luciferase assays were carried out with 50 µl lysate using the dual-luciferase reporter assay system (Promega) in a chemiluminescence analyzer (FB12 luminometer; Berthold Detection Systems, Germany). Luciferase activities were expressed as fold induction relative to values obtained from control cells. The results represented the mean of at least three independent transfection experiments, each carried out in duplicate. Renilla luciferase activity was used as an internal control for transfection efficiency.

Preparation of nuclear extracts and electrophoretic mobility shift assays (EMSAs)
HepG2 cells were transfected with various amount of pcDNA3.1-HMGB1FL or derivatives of HMGB1 and nuclear extracts were isolated as described previously (25). In each case, pcDNA3.1 was added as necessary to keep the total amount of transfected plasmids fixed. The DNA probe was prepared by annealing two oligonucliotides 5'-GCTATGCTGTTAATTATTGGCA-3' and 5'-TGCCAATAATTAACAGCATAGC- 3', which correspond to both strands of HNF1{alpha} recognition consensus sequence in the promoter of AFP (3,4), and labeling them with [{gamma}-32P] ATP by filling in the T4 polynucleotide kinase (Gel Shift Assay System, Promega). Nuclear extracts (10 µg) were incubated with the binding buffer for 10 min, followed by incubation with 0.5 ng of 32P-labeled DNA probe for 30 min at room temperature. The DNA–protein complexes were analyzed by electrophoresis on a 4% polyacrylamide gel in 0.5xTris–borate/ethylene diaminetetraacetic acid (EDTA) electrophoresis buffer at 300 V followed by autoradiography. For competition experiments, extracts were preincubated with a 50-fold excess of unlabeled double-stranded oligonucleotides. In supershift assays, 2 µg of antibodies against HNF1{alpha} (sc-6547X, Santa Cruz Biotechnology) were added to the nuclear extracts 30 min before the addition of radiolabeled probes.

Chromatin-immunoprecipitation (ChIP) assays
In this assay, 107 HepG2 cells were lyzed with cell lysis buffer (10 mM Tris–HCl, pH 8.0; 10 mM NaCl; 0.2% NP-40) on ice for 10 min, centrifuged at 2500 r.p.m. for 5 min at 4°C, resuspended in nuclear lysis buffer (50 mM Tris–HCl, pH 8.0; 10 mM EDTA; 1% SDS), vortexed three times, sonicated six times to shear chromatin and centrifuged at 12 000 r.p.m. for 15 min at 4°C. The supernatant were collected as the whole-cell extract (WCE).

Protein–DNA immunocomplexes were immunoprecipitated with rabbit polyclonal antibodies against HNF1{alpha} (sc-8986, Santa Cruz Biotechnology) or rabbit polyclonal antibodies against HMGB1 (BC003378 [GenBank] , Protein Tech Group, IL) or rabbit IgG (sc-2027, Santa Cruz Biotechnology). WCE measuring 100 µl were incubated with antibodies in 900 µl ChIP dilution buffer (0.01% SDS, 1.1% Triton-X 100, 1.2 mM EDTA, 16.7 mM Tris–HCl, pH 8.0, 167 mM NaCl), with protein A/G agarose beads as an adsorbent. Resins were washed with serious buffers containing various detergents and NaCl in different concentrations. Following elution, DNA fragments were isolated and purified using phenol/chloroform. PCR was conducted using primers AFP-F (–282): 5'-GCGAGATCTTCTGCAACTTAGGGACAA-3' and AFP-R (+32): 5'-GCGAAGCTTGTTATTGGCAGTGGTGGA-3' under the following conditions: 28 cycles, 59°C, 5 U Taq polymerase and 25 pmol of each primer. Amplified products were analyzed on 1.5% Tris–borate/EDTA-agarose gels.

Statistical analysis
Statistical analysis was performed using the Student's t-test. P < 0.05 was considered significant. Data were expressed as mean ± SEM.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 SUPPLEMENTARY DATA
 REFERENCES
 
IP-MS strategy allows the identification of novel HNF1{alpha}-binding partners
In an effort to detect proteins interacting with HNF1{alpha}, we developed a co-IP-MS strategy to search HNF1{alpha} interactions in vivo. HNF1{alpha}-containing protein complex was immunoprecipitated from human hepatoma cell line HepG2 cells using HNF1{alpha} antibody and HNF1{alpha} in the immunoprecipitation complex was identified by western blotting (data not shown). To determine whether containing reported interactors of HNF1{alpha} in the HNF1{alpha}-containing protein complex, HNF4, an admitted cofactor of HNF1{alpha}, was verified in the HNF1{alpha}–IP complex by western blotting (data not shown). Then, protein complexes were separated by SDS–PAGE, and stained with Coomassie bright blue (Supplementary Data 2). Differential blue color bands were excised, trypsinized and analyzed through microcapillary liquid chromatography MS/MS followed by protein database searching of the generated spectra. We set up the criteria for a minimum two unique peptides per positive protein identification, and we reported only those proteins that were identified in at least two independent experiments. After performing MS/MS, a total of 18 nonredundant proteins were found to interact with HNF1{alpha} compared to the control (Table 1). To confirm the novel interactors of HNF1{alpha}, we selected four of the novel HNF1{alpha}-binding partners (RANBP1, 14-3-3zeta, CBX3, HMGB1) for half-in vivo co-immunoprecipitation in HepG2 cells. Immunoblotting analysis showed that HNF1{alpha} were co-immunoprecipitated with all four proteins (data not shown). These results indicate that the IP-MS strategy in our study could be effective.


View this table:
[in this window]
[in a new window]

  		Table 1. List of proteins identified in co-immunoprecipitated HNF1{alpha} complex by MS/MS

 
Identification of HMGB1 interacting with HNF1{alpha} in vivo
To assess the intracellular association of HNF1{alpha} with HMGB1, a half-in vivo co-immunoprecipitation was performed. HepG2 cells were transfected with pcDNA3.1-HMGB1 or pcDNA3.1/Myc-HisB, and then the cell lysates were subjected to immunoprecipitation with anti-Myc antibody and western blotting with anti-HNF1{alpha} antibody. Immunoblotting analysis showed that HNF1{alpha} was co-immunoprecipitated with HMGB1 (Figure 1A and B). To further confirm this association, colocalization of HNF1{alpha} and HMGB1 was studied. As shown in Figure 1C, HNF1{alpha} and HMGB1 showed colocalization when the images were merged. These results indicate that HMGB1 interacts specifically with HNF1{alpha} in vivo.


Figure 1
View larger version (15K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 1. Analysis of interaction between HNF1{alpha} and HMGB1. HepG2 cells were transfected with pcDNA3.1-HMGB1 or pcDNA3.1-Myc/HisB, and after 48 h, cell lysates were prepared and immunoprecipitations were performed with anti-Myc antibody. Immunoprecipitates were analyzed with anti-Myc antibody (A) and anti-HNF1{alpha} antibody (B). The positions of HMGB1, HNF1{alpha} and the IgG were indicated by an arrow. (C) HepG2 cells were co-transfected with GFP-HMGB1 and Myc-HNF1{alpha} for 24 h. Immunofluorescence staining was performed with anti-Myc monoclonal antibody to analyze the localization of HNF1{alpha}. The locations of HMGB1 (green) and HNF1{alpha} (red) were observed through confocal imaging. Scale bar: 10 µm.

 
Mapping the binding site of HNF1{alpha} and HMGB1
To map the domain of HNF1{alpha} protein required for interaction with HMGB1, we performed GST pull-down assay using GST fusion proteins containing deletion mutants of HNF1{alpha} with HMGB1 or HMGA2, which is another nonhistone chromosomal high mobility group (HMG) protein family member and was regarded as irrelevant negative control. HNF1{alpha} consists of several domains such as dimerization, homeobox and transactivation domains (Figure 2A). For this purpose, various fragment of HNF1{alpha} was constructed into pGEX4T2. GST and GST fusion proteins were expressed in E. coli BL21 and purified using glutathione-Sepharose beads according to the manufacturer's instructions, as judged by Coomassie bright blue staining (Figure 2B). Myc-HMGB1FL was pulled down with GST-HNF1{alpha}{Delta}190-319 whereas not with those with amino acid residues 1–189 or 320–631 (Figure 2C). These findings demonstrate that fragment 190–319aa of HNF1{alpha}, containing the homeobox domain is responsible for the interaction with HMGB1. All derivatives of HNF1{alpha} did not pull down with HMGA2, which suggested the specific interaction between HNF1{alpha} and HMGB1 (Figure 2C).


Figure 2
View larger version (22K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 2. Mapping the binding site of HNF1{alpha} and HMGB1. (A) Schematic representation of domain structure of HNF1{alpha}. (B) GST, GST-HNF1{alpha}{Delta}1-189, GST-HNF1{alpha}{Delta}190-319 and GST-HNF1{alpha}{Delta}320-631 fusion proteins were expressed in E. coli, purified by glutathione-Sepharose beads. The complexes were washed to remove noninteracting proteins, electrophoresed in SDS–PAGE and visualized by Coomassie bright blue staining. (C) Lysates of HepG2 cells that were transfected with pcDNA3.1-HMGB1FL or pcDNA3.1-HMGA2 were incubated with the following fusion proteins, respectively, including GST alone, GST-HNF1{alpha}{Delta}1-189, GST-HNF1{alpha}{Delta}190-319 and GST-HNF1{alpha}{Delta}320-631. Whole-cell lyses were extracted and digested with DNase I and performed GST pull down. Complexes were detected by western blotting analysis using anti-Myc antibody. (D) Schematic representation of domain structure of HMGB1 was shown. HepG2 cells were transfected with pcDNA3.1-HMGB1FL, pcDNA3.1-HMGB1{Delta}8-161, pcDNA3.1-HMGB1{Delta}8-77 or pcDNA3.1-HMGB1{Delta}92-161, respectively. Twenty-four hours later, whole-cell lyses were extracted and digested with DNase I and performed GST pull-down. Cell lysates of pcDNA3.1-HMGB1FL were pulled down by GST-HNF1{alpha}{Delta}190-319 fusion protein and were not pulled down by GST alone. Cell lysates of pcDNA3.1-HMGB1{Delta}8-161 were pulled down by GST-HNF1{alpha}{Delta}190-319 fusion protein and not pulled down by GST alone. Cell lysates of pcDNA3.1-HMGB1{Delta}8-77 were pulled down by GST-HNF1{alpha}{Delta}190-319 fusion protein and not pulled down by GST alone. Cell lysates of pcDNA3.1-HMGB1{Delta}92-161 were pulled down by GST-HNF1{alpha}{Delta}190-319 fusion protein and not pulled down by GST alone.

 
To map the domain of HMGB1 protein required for interaction with HNF1{alpha}, we performed another GST pull-down assay. HMGB1 is structured into two HMG box domains plus a highly acidic C-terminal region (Figure 2D). We therefore generated the following four Myc-tagged proteins: full-length HMGB1, HMGB1{Delta}8-161, HMGB1{Delta}8-77 and HMGB1{Delta}92-161. As expected, HMGB1FL exhibited specific binding to HNF1{alpha}{Delta}190-319 (Figure 2D). It was further revealed that HMGB1{Delta}8-161, HMGB1{Delta}8-77 and HMGB1{Delta}92-161 were capable of binding (Figure 2D), indicating that a single HMG box was sufficient for the interaction and that the acidic tail was not required. Together, these results suggest that the HMG box of HMGB1 and the homeobox domain of HNF1{alpha} are necessary for the interaction between HNF1{alpha} and HMGB1.

HMGB1 enhances HNF1{alpha}-mediated transactivation
The existence of functional interaction between HNF1{alpha} and HMGB1 was analyzed in cell culture transfection assays. As previously reported (3,4,6), promoter region of AFP included several binding sites for HNF1{alpha} protein, and HNF1{alpha} gene product activated transcription of AFP-reporter gene in transient co-transfection assays. In a typical experiment, HNF1{alpha}, expressed from the CMV promoter-driven construct, activated transcription of pGL3-AFP reporter 73-fold over the basal level (Figure 3, P < 0.05), and HMGB1 by itself showed little effect on the transcription activity of the pGL3-AFP reporter. However, co-transfection of HNF1{alpha} together with HMGB1 expression construct led to a strong stimulation of the reporter activity, up to 187-fold over the basal level (Figure 3, P < 0.05) and to 2–3-fold over the maximum level obtained with HNF1{alpha} alone. Co-transfection of HNF1{alpha} with HMGB1{Delta}8-161 stimulated the reporter activity up to 140-fold over the basal level (Figure 3, P < 0.05). Co-transfection of HNF1{alpha} with HMGB1{Delta}92-161 activated the reporter activity up to 170-fold over the basal level (Figure 3, P < 0.05). However, only little effect was shown on the transcription activity of the pGL3-AFP reporter when HNF1{alpha} co-transfected with HMGB1{Delta}8-77 (Figure 3, P < 0.05). These functional studies demonstrate that HMGB1 potentiates the transcriptional activities of HNF1{alpha} and suggest a functional interaction that exist between HNF1{alpha} and the second HMG box domain (HMGB1{Delta}92-161) of HMGB1.


Figure 3
View larger version (13K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 3. HMGB1 enhanced HNF1{alpha}-mediated transcription. HepG2 cells were co-transfected with 400 ng pGL3-AFP reporter vector, 20 ng HNF1{alpha} expression vector and 800 ng HMGB1FL expression vector or HMGB1{Delta}8-161 expression vector or HMGB1{Delta}8-77 expression vector or HMGB1{Delta}92-161 expression vector or control vector, and then the luciferase activity was measured (P < 0.05). The results were shown as the mean ± SEM of triplicate experiments.

 
HMGB1 facilitates the binding of HNF1{alpha} to its target sequences
To understand the mechanism of enhancement of HNF1{alpha} activity by HMGB1, we examined the effect of HMGB1 on the DNA-binding ability of HNF1{alpha}. EMSA with nuclear extracts from HepG2 cells which were transfected with pcDNA3.1-HMGB1FL or derivatives of HMGB1 and the 32P-labeled fragment of DNA covering the –138/–119 AFP promoter sequence was performed. As shown in Figure 4A, specific DNA–protein complexes were reproducible detected. When HMGB1 was added, the intensities of bands enhanced in a dose-dependent manner, indicating that HMGB1 stimulated HNF1{alpha} binding to the –138/–119 AFP promoter region (lanes 2–6 in Figure 4A). It was also remarkable that pcDNA3.1-HMGB1FL did not change the mobility, suggesting that HMGB1 was not included in the protein–DNA complex, or separated very fast. To observe which HMGB1 domain donated to the enhancement, we operated another EMSA. As shown in Figure 4C, compared with control (pcDNA3.1, lane 3), the bands intensities of HNF1{alpha}–DNA complex were enhanced by addition of HMGB1FL (lane 2) and its derivatives, containing the two HMG boxes (HMGB1{Delta}8-161, lane 4), or HMG box B (HMGB1{Delta}92-161, lane 6). Moreover, the addition of HMGB1{Delta}92-161 protein resulted in an enhancement of HNF1{alpha} binding in a dose-dependent manner (lanes 9–11). On the other hand, HMGB1{Delta}8-77 could not increase HNF1{alpha} DNA-binding ability (lane 5). Thus, HMGB1{Delta}92-161 (box B) played a major role in promoting the formation of the HNF1{alpha} protein–DNA complex. Competition experiments with an excess of nonradioactive-labeled HNF1{alpha} recognition sequence completely led to the disappearance of the protein–DNA complexes (lane 7 in Figure 4A and C). Supershift experiments were performed to identify HNF1{alpha}, which was bound in the protein–DNA complexes (lane 8 in Figure 4A and C). Western blotting analysis was presented to reflect the amounts of HMGB1FL and HMGB1{Delta}92-161 (Figure 4B and D) in reaction.


Figure 4
Figure 4
View larger version (55K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 4. HMGB1 enhanced HNF1{alpha} DNA-binding activity. (A) HepG2 cells were transfected with various amounts of HMGB1FL (lane 2: 4 µg, lane 3: 3 µg, lane 4 2 µg, lane 5: 1 µg and lane 6: 0 µg). Control vector was added as necessary to maintain the amount of transfected plasmids constant. After 24 h, nuclear extracts were prepared to analysis the binding to 32P-labeled probe by electrophoretic mobility shift assay (EMSA). The annealed oligonucleotides contained the sequence between –138 and –119 of the AFP promoter. The 32P-labeled oligonucleotides were incubated with the indicated nuclear extracts and/or antibody and resolved on a 4% polyacrylamide gel. Lanes 2–6 showed that increasing amounts of HMGB1FL protein enhanced DNA binding of HNF1{alpha} in a dose-dependent manner. The intensity quantity was measured by densitometry and the results were graphed as fold of changes compared with control (pcDNA3.1, lane 6). (B) Western blotting was executed to manifest the amount of HMGB1 in each reaction. (C) EMSA were performed as described for (A), using nuclear extracts derived from HepG2 cells which were transfected with 4 µg various deletion derivatives of HMGB1 (lane 2: HMGB1FL, lane 3: pcDNA3.1, lane 4: HMGB1{Delta}8-161, lane 5: HMGB1{Delta}8-77 and lane 6: HMGB1{Delta}92-161). Lanes 9–11 showed that increasing amounts of HMGB1{Delta}92-161 protein enhanced DNA binding of HNF1{alpha} in a dose-dependent manner (lane 9: 1 µg, lane 10: 2 µg, lane 11: 3 µg). The intensity quantity was measured by densitometry and the results were graphed as fold of changes compared with control (pcDNA3.1, lane 3). Control vector was added to keep the transfected plasmids amounts equal to 4 µg. (D) Western blotting was fulfilled to exhibit the amount of HMGB1{Delta}92-161. Lane 1 in both (A) and (C) represented control lanes in which the oligonucleotide probes were not incubated with any nuclear extracts. Competition experiments were carried out with 50-fold excess of unlabeled oligonucleotide [lane 7 in (A) and (C)]. For supershift experiments, nuclear extracts were incubated with antibodies specific for HNF1{alpha} [lane 8 in (A) and (C)].

 
HMGB1 is recruited to endogenous AFP promoters
To precisely understand the interaction between HNF1{alpha} and HMGB1, ChIP was used to determine whether HMGB1 was recruited by HNF1{alpha} to the HNF1{alpha}-dependent promoter in vivo. Previous studies showed that HNF1{alpha} recognition sites located at the region from –132 to –118 bp in AFP promoter (3,4,6). Following formaldehyde cross-linking and chromatin precipitation with respective antibodies, the precipitated DNA was amplified with specific primers (Supplementary Data 1). The region from –282 bp to +32 bp upstream of AFP promoter was enriched for HNF1{alpha} and HMGB1 binding. No binding of IgG was observed in AFP sequences (Figure 5A). HNF1{alpha} immunoprecipitated complex and HMGB1–IP complex were detected with western blotting analysis using HNF1{alpha} and HMGB1 antibodies (Figure 5B). We conclude that HMGB1 is specifically recruited by HNF1{alpha} to the AFP promoter and responsible for HNF1{alpha}-dependent transactivation.


Figure 5
View larger version (44K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 5. HNF1{alpha} and HMGB1 physically interacted and were recruited to AFP promoter in vivo. (A) Specific recruitment of HMGB1 by HNF1{alpha} by ChIP assays in HepG2 cells. Primers specific for the AFP promoter (–282 bp to +32 bp) were used to amplify the DNA associated with HNF1{alpha} and HMGB1 in vivo. (B) Cleared whole-cell extract was first incubated with control IgG, anti-HNF1{alpha} or anti-HMGB1 antibody, then with protein A/G agarose as an adsorbent. Bound proteins were detected by immunoblotting with antibodies to HNF1{alpha} or HMGB1.

 
RNA interference of HMGB1 leads to altered expression of HNF1{alpha} target genes
To further confirm the role for HMGB1 in the regulation of HNF1{alpha} target genes in vivo, we performed RNA interference assay to investigate whether the decrease of HMGB1 expression altered expression of other known HNF1{alpha} target genes. As Figure 6A and B, and Table 2 showed, transfection with siRNA directed against HMGB1 into HepG2 cells reduced the level of HMGB1 protein by 70% (P < 0.05). However, transfection with nonspecific RNA only slightly decreased the level of HMGB1 protein. The levels of HNF1{alpha} protein or β-actin were not affected by these siRNAs. As shown in Figure 6C, when endogenous HMGB1 expression was knocked down by RNAi, the activity of pGL3-AFP reporter was reduced 60% in parallel (P < 0.05). Moreover, HMGB1 downregulation inhibited expression of ALB, AFP, A1AT, FGA, PAH, GLUT2, LPK, IGFBP1 and APOC3 genes (Figure 6D and Table 2, P < 0.05), which was consistent with previous observations that HNF1{alpha} positively regulated expression of these genes (4–6,13–15). However, the HMGB1 downregulation did not affect expression of PEPCK genes (Figure 6D and Table 2, P > 0.05), which was regulated by the AREBP, C/EBP and ATF-2 (26). These results indicate that HMGB1 specifically modulates expression of HNF1{alpha} target genes.


Figure 6
View larger version (20K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Figure 6. Suppression of HMGB1 decreases HNF1{alpha}-mediated transcription. (A and B) HepG2 cells were transfected with HMGB1 siRNA or nonspecific RNA duplex for 60 h. HMGB1 expression was detected by immunoblotting with β-actin as the internal control and real-time PCR with GAPDH as the internal control. PCR was performed in triplicates, and results were normalized to the endogenous control. Fold induction represented the relative expression (P < 0.05) of HMGB1. The results were the mean ± SEM of triplicate experiments. (C) HepG2 cells were co-transfected with 400 ng pGL3-AFP and 20 pmol siHMGB1 or nonspecific RNA duplex, and then the luciferase activity was measured (P < 0.05). The results were shown as the mean ± SEM of triplicate experiments. (D) Suppression of HMGB1 decreased the expression of HNF1{alpha} target genes. Real-time PCR using primer sets specific for ALB, AFP, A1AT, APOC3, FGA, GLUT2, LPK, IGFBP1, PAH, PEPCK and GAPDH. GAPDH was used as the internal control. HepG2 cells were seeded in 6-well plates and transfected with 100 pmol HMGB1 siRNA or nonspecific duplex for 60 h. Total RNA were extracted and reverse transcripted. PCR was performed in triplicates, and results were normalized to the endogenous control. Fold induction represented the relative expression (P < 0.05) of ALB, AFP, A1AT, APOC3, FGA, GLUT2, LPK, IGFBP1, PAH and PEPCK mRNA in HMGB1 siRNA-treated HepG2 cells over that of nonspecific duplex-treated controls. The results were the mean ± SEM of triplicate experiments.

 

View this table:
[in this window]
[in a new window]

  		Table 2. Analysis of the mRNA level of gene by real-time PCR

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
SUPPLEMENTARY DATA
 REFERENCES
 
Protein–protein interactions are essential for HNF1{alpha}-mediated transcription regulation. Studies on the mutations in HNF1{alpha}, which result in MODY3, raise a possibility that the in vivo protein–protein interaction is a critical determinant of gene activation by HNF1{alpha} (27). A few nuclear proteins that act as modulators of HNF1{alpha}-regulated transcription have been identified (17–22). However, the defects in gene regulation resulting from the disruption of interaction between HNF1{alpha} and its cofactors are largely unknown. In the present study, we demonstrate that HMGB1 is a new cofactor of HNF1{alpha}, which interacts with HNF1{alpha}, enhances its binding to cognate DNA sequences and improves its transcriptional activity.

HMGB1, historically known as an abundant, nonhistone architectural chromosomal protein, is extremely conserved across species (28). As a nuclear protein, HMGB1 stabilizes nucleosomes and allows bending of DNA to facilitate gene transcription. In fact, HMGB1 has been implicated in the regulation of transcription, via both activation and repression. It has been documented that HMGB1 interacted both with the basal transcription machinery (29) and with individual transcription factors such as Hox proteins, p53, NF-{kappa}B and steroid hormone receptors (24,30–34). HMGB1 binds transiently to DNA, prebends DNA into thermodynamically unfavorable conformation and offers DNA to the transcription factor, which will eventually form a stable complex with DNA. In our series of experiments, we found that the homeodomain of HNF1{alpha} and HMG box of HMGB1 were their interaction fragments. Previous reports on regulation of HNF1{alpha} interactions with DNA have implicated its homeodomain in Cdx2 positive regulating DNA binding (21). Involvement of the homeodomain in both DNA binding and protein–protein interaction also has been observed, as in Pit-1–Oct interaction (35). It has been documented that some Hox proteins, such as Oct protein, TBP or steroid receptor, could interact with HMGB1 through either HMG box A (8–77aa) or HMG box B (92–161aa) domain of HMGB1 (24,32,33). In the present study, we also determined that HNF1{alpha} directly interacted with box A and box B of HMGB1. Both HMG box A and box B are HMGB1 DNA-binding domains. Either box A or box B of HMGB1 enhanced the HoxD9-mediated transactivation alone(33). In our studies, we found that HMGB1 enhanced HNF1{alpha}-mediated transcription depended heavily on HMG box B of HMGB1. Data from ChIP and EMSA demonstrated that HMGB1 was recruited to endogenous HNF1{alpha}-responsive promoters and increased the DNA-binding activity of HNF1{alpha}. We then propose that HMGB1 might be recruited by HNF1{alpha} protein and the physical contact between the homeodomain and one HMG box directs these two DNA-binding domains to adjacent or overlapping DNA segments, generating a complex, which might contribute to the enhanced binding of HNF1{alpha} to its targeting site. Moreover, a downregulation of HNF1{alpha} target genes expression after knockdown of endogenous HMGB1 with siRNAs strongly supports an important role of HMGB1 as a physiological cofactor of HNF1{alpha}. The different extents of suppression by HMGB1 RNAi knockdown on HNF1{alpha} targets may be due to different transcription regulation mechanism of target genes. For example, the tissue specificity of ALB gene expression is regulated by the synergistic activation of HNF1{alpha} and CEBPA (36); IL-6-mediated IGFBP1 promoter activation is via the intact HNF1-binding site and is dependent on the presence of endogenous HNF1{alpha} and STAT3 and AP-1 (c-Fos/c-Jun) (37); HNF1{alpha} recruits p300 to transactive the expression of GLUT2 gene (38).

Previous studies have shown that HMGB1 played an important role in the regulation of lipogenic, cholesterogenic and acute phase (AP) responsive genes transcription (24). The responsibility of HNF1{alpha} in cholesterol homeostasis is important as well, in which HNF1{alpha} is a key regulator of multiple pathways essential for the maintenance of normal plasma cholesterol levels, including bile acid synthesis, bile acid uptake by the liver, intestines and kidney, and HDL-cholesterol metabolism (39). It has been documented that homozygous knockout mice of the HMGB1 gene were born alive, but died within 24 h due to hypoglycemia (40). MODY-associated HNF4{alpha} mutations caused increased insulin secretion in the fetal and neonatal period, resulting in increased birthweight and neonatal hypoglycemia (41). To some extent, HNF4{alpha} mutation will produce the same result as HNF1{alpha}-mediated negative regulation. Therefore, the phenotype of Hmgb1–/– mice provides evidence that the interaction between HNF1{alpha} and HMGB1 should be critical for HNF1{alpha}-dependent regulation. Supporting this, HMGB1 downregulation by RNA interference specifically affected the HNF1{alpha}-dependent gene expression in HepG2 cells. Our present findings thus raise the possibility that HMGB1 might be potentially involved in this dynamic regulation of hepatic genes expression.

In summary, we have identified HMGB1 as a novel interactor for HNF1{alpha}, which enhanced its binding to cognate DNA sequences and transcriptional activity. Investigation of this interaction between HMGB1 and HNF1{alpha} protein will give valuable insights into yet undiscovered roles of HMGB1 in the regulation of transcription and hepatic function.


   SUPPLEMENTARY DATA
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 SUPPLEMENTARY DATA
REFERENCES
 
Supplementary data are available at NAR Online.


   ACKNOWLEDGEMENTS
 
This work was partially supported by the Special Funds for Major State Basic Research of China (2006CB910802), National HighTec Research Developing Programme (2006AA02A310) and Chinese National Natural Science Fund for the Popularization of Science (30321003). Funding to pay the Open Access publication charges for this article was provided by the Special Funds for Major State Basic Research of China (2006CB910802).

Conflict of interest statement. None declared.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 SUPPLEMENTARY DATA
 REFERENCES
 

  1. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol. Rev (2002) 54:129–158.[Abstract/Free Full Text]

  2. Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J (1996) 10:267–282.[Abstract]

  3. Mendel DB, Crabtree GR. HNF-1, a member of a novel class of dimerizing homeodomain proteins. J. Biol. Chem (1991) 266:677–680.[Free Full Text]

  4. Sawadaishi K, Morinaga T, Tamaoki T. Interaction of a hepatoma-specific nuclear factor with transcription-regulatory sequences of the human {alpha}-fetoprotein and albumin genes. Mol. Cell Biol (1988) 8:5179–5187.[Abstract/Free Full Text]

  5. Ktistaki E, Talianidis I. Modulation of hepatic gene expression by hepatocyte nuclear factor 1. Science (1997) 277:109–112.[Abstract/Free Full Text]

  6. Courtois G, Baumhueter S, Crabtree GR. Purified hepatocyte nuclear factor 1 interacts with a family of hepatocyte-specific promoters. Proc. Natl Acad. Sci. USA (1988) 85:7937–7941.[Abstract/Free Full Text]

  7. Kritis AA, Ktistaki E, Barda D, Zannis VI, Talianidis I. An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression. Nucleic Acids Res (1993) 21:5882–5889.[Abstract/Free Full Text]

  8. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science (2004) 303:1378–1381.[Abstract/Free Full Text]

  9. Kulkarni RN, Kahn CR. HNFs-linking the liver and pancreatic islets in diabetes. Science (2004) 303:1311–1312.[Abstract/Free Full Text]

  10. Duncan SA, Navas MA, Dufort D, Rossant J, Stoffel M. Regulation of transcription factor network required for differentiation and metabolism. Science (1998) 281:692–695.[Abstract/Free Full Text]

  11. Yang Q, Yamagata K, Fukuim K, Cao Y, Nammo T, Iwahashi H, Wang H, Matsumura I, Hanafusa T, et al. Hepatocyte nuclear factor-1{alpha} modulates pancreatic β-cell growth by regulating the expression of insulin-like growth factor-1 in INS-1 cells. Diabetes (2002) 5:1785–1792.

  12. Bjorkhaug L, Sagen JV, Thorsby P, Sovik O, Molven A, Njolstad PR. Hepatocyte nuclear factor-1{alpha} gene mutations and diabetes in Norway. J. Clin. Endocrinol. Metab (2003) 88:920–931.[Abstract/Free Full Text]

  13. Shih DQ, Screenan S, Munoz KN, Philipson L, Pontoglio M, Yaniv M, Polonsky KS, Stoffel M. Loss of HNF-1{alpha} function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes (2001) 50:2472–2480.[Abstract/Free Full Text]

  14. Wang H, Maechler P, Hagenfeldt KA, Wollheim CB. Dominant-negative suppression of HNF1{alpha} function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic β-cell line. EMBO J (1998) 17:6701–6713.[CrossRef][Web of Science][Medline]

  15. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal fanconi syndrome. Cell (1996) 84:575–585.[CrossRef][Web of Science][Medline]

  16. Mendel DB, Hansen LP, Graves MK, Conley PB, Crabtree GR. HNF-1{alpha} and HNF-1β (vHNF-1) share dimerization and homeo domains, but not activation domains, and form heterodimers in vitro. Genes Dev (1991) 5:1042–1056.[Abstract/Free Full Text]

  17. Sourdive DJD, Transy C, Garbay S, Yaniv M. The bifunctional DCOH protein binds to HNF1 independently of its 4-{alpha}- carbinolamine dehydratase activity. Nucleic Acids Res (1997) 25:1476–1484.[Abstract/Free Full Text]

  18. Soutoglou E, Papafotiou G, Katrakili N, Talianidis I. Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J. Biol. Chem (2000) 275:12515–12520.[Abstract/Free Full Text]

  19. Dohda T, Kaneoka H, Inayoshi Y, Kamihira M, Miyake K, Iijima S. Transcriptional coactivators CBP and p300 cooperatively enhance HNF-1{alpha}- mediated expression of the albumin gene in hepatcytes. J. Biochem (2004) 136:313–319.[Abstract/Free Full Text]

  20. Smith SB, Gasa R, Watada H, Wang J, Griffen SC, German MS. Neruogenin3 and hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4. J. Biol. Chem (2003) 278:28254–28259.

  21. Mitchelmore C, Troelsen JT, Spodsberg N, Sjostrom H, Noren O. Interaction between the homeodomain proteins Cdx2 and HNF1{alpha} mediates expression of the lactase-phlorizin hydrolase gene. Biochem. J (2000) 346:529–535.[CrossRef][Web of Science][Medline]

  22. van Wering HM, Huibregtse IL, van der Zwan SM, de Bie MS, Dowling LN, Boudreau F, Rings EH, Grand RJ, Krasinski SD. Physical interaction between GATA-5 and hepatocyte nuclear factor-1{alpha} results in synergistic activation of the human lactase-phlorizin hydrolase promoter. J. Biol. Chem (2002) 277:27659–27667.[Abstract/Free Full Text]

  23. Magee TR, Cai Y, El-Houseini ME, Locker J, Wan Yu-Jui Y. Retinoic acid mediates down-regulation of the {alpha}-fetoprotein gene through decreased expression of hepatocyte nuclear factors. J. Biol. Chem (1998) 273:30024–30032.[Abstract/Free Full Text]

  24. Najima Y, Yahagi N, Takeuchi Y, Matsuzaka T, Sekiya M, Nakagawa Y, Amemiya-Kudo M, Okazaki H, Okazaki S, et al. High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding. J. Biol. Chem (2005) 280:27523–27532.[Abstract/Free Full Text]

  25. Zeissig S, Fromm A, Mankerta J, Weiske J, Zeita M, Fromm M, Schulzke J. Butyrate induces intestinal sodium absorption via Sp3-mediated transcriptional up-regulation of epithelial sodium channels. Gastroenterology (2007) 132:236–248.[Medline]

  26. Lee MY, Jung CH, Lee K, Choi YH, Hong S, Cheong J. Activating transcription factor-2 mediates transcriptional regulation of gluconeogenic gene PEPCK by retinoic acid. Diabetes (2002) 51:3400–3407.[Abstract/Free Full Text]

  27. Divine JK, McCaul SP, Simon TC. HNF-1{alpha} and endodermal transcription factors cooperatively activate Fabpl: MODY3 mutations abrogate cooperativity. Am. J. Physiol. Gastrointest. Liver Physiol (2003) 285:G62–G72.[Abstract/Free Full Text]

  28. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell Biol (1999) 19:5237–5246.[Free Full Text]

  29. Ge H, Roeder RG. The high mobility group protein HMG1 can rebersibly inhibit class II gene transcription by interaction with the TATA-binding protein. J. Biol. Chem (1994) 269:17136–17140.[Abstract/Free Full Text]

  30. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol. Cell Biol (1998) 18:4471–4487.[Abstract/Free Full Text]

  31. Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem (2002) 277:7157–7164.[Abstract/Free Full Text]

  32. Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem. Biophys. Res. Commun (2003) 302:421–426.[CrossRef][Web of Science][Medline]

  33. Zappavigna V, Falciola L, Citterich MH, Mavilio F, Bianchi ME. HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J (1996) 15:4981–4991.[Web of Science][Medline]

  34. Zwilling S, Konig H, Wirth T. High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. EMBO J (1995) 4:1198–1208.

  35. Stern S, Tanaka M, Herr W. The Oct-1 homeodomain directs formation of a multiprotein-DNA complex with the HSV transactivator VP16. Nature (1989) 341:624.[CrossRef][Medline]

  36. Wu KJ, Wilson DR, Shih C, Darlington GJ. The transcription factor HNF1 acts with C/EBP alpha to synergistically activate the human albumin promoter through a novel domain. J. Biol. Chem (1994) 269:1177–1182.[Abstract/Free Full Text]

  37. Leu JI, Crissey MA, Leu JP, Ciliberto G, Taub R. Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol. Cell. Biol (2001) 21:414–424.[Abstract/Free Full Text]

  38. Ban N, Yamada Y, Someya Y, Miyawaki K, Ihara Y, Hosokawa M, Toyokuni S, Tsuda K, Seino Y. Hepatocyte nuclear factor-1alpha recruits the transcriptional co-activator p300 on the GLUT2 gene promoter. Diabetes (2002) 51:1409–1418.[Abstract/Free Full Text]

  39. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, et al. Hepatocyte nuclear factor-1{alpha} is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet (2001) 27:375–382.[CrossRef][Web of Science][Medline]

  40. Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, Bianchi ME. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet (1999) 22:276–280.[CrossRef][Web of Science][Medline]

  41. Glaser B. Type 2 diabetes: hypoinsulinism, hyperinsulinism, or both? PLoS Med (2007) 4:0619–0620.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
A. J. Michels and T. M. Hagen
Hepatocyte nuclear factor 1 is essential for transcription of sodium-dependent vitamin C transporter protein 1
Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1220 - C1227.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
I. M. Bochkis, J. Schug, N. E. Rubins, A. R. Chopra, B. W. O'Malley, and K. H. Kaestner
Foxa2-dependent hepatic gene regulatory networks depend on physiological state
Physiol Genomics, July 9, 2009; 38(2): 186 - 195.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-T. Yu, M. Yu, C.-Y. Li, Y.-Q. Zhan, W.-X. Xu, Y.-H. Li, W. Li, Z.-D. Wang, C.-H. Ge, and X.-M. Yang
Specific Expression and Regulation of Hepassocin in the Liver and Down-regulation of the Correlation of HNF1{alpha} with Decreased Levels of Hepassocin in Human Hepatocellular Carcinoma
J. Biol. Chem., May 15, 2009; 284(20): 13335 - 13347.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Print PDF (4366K) Freely available
Right arrow Screen PDF (421K) Freely available
Right arrow Supplementary Data
Right arrowOA All Versions of this Article:
36/4/1209    most recent
gkm1131v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Yu, M.
Right arrow Articles by Yang, X. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, M.
Right arrow Articles by Yang, X. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?